The American Association of Clinical Endocrinology (AACE) has released its 2025 Consensus Statement and updated algorithm for the management of adults with dyslipidemia, offering concise visual guidance and tables to support clinical decision-making aimed at reducing atherosclerotic cardiovascular disease (ASCVD) and triglyceride-induced pancreatitis risk. Developed by an international multidisciplinary task force, the update builds upon the 2020 AACE algorithm and integrates current evidence and expert consensus. The 2025 algorithm outlines guiding principles for patient-centered management, comprehensive risk assessment, identification of genetic dyslipidemias, lifestyle interventions, LDL-cholesterol–lowering pharmacotherapy, approaches to statin-associated muscle symptoms, and management strategies for hypertriglyceridemia and special populations—including older adults, those receiving transgender care or HIV treatment, and pregnant or lactating individuals. Aligned with the 2025 AACE Clinical Practice Guideline for Pharmacologic Management of Dyslipidemia and consistent with other international guidance, this update emphasizes individualized therapy, ASCVD and pancreatitis risk assessment, and the integration of health equity, cost-effectiveness, and risk–benefit considerations into dyslipidemia management. Source: https://www.endocrinepractice.org/
A circadian subtype of depression is associated with earlier disease onset, more severe clinical features,…
A longitudinal study of 995 U.S. older adults found that frequent and unintentional daytime napping…
A multicohort genetic association study found that the ancestry-enriched CD36 Y325* variant accounted for a…
An American College of Cardiology scientific statement emphasizes that exercise should be prescribed as a…
A 16-week low-fat vegan diet was associated with significant reductions in body weight, visceral fat,…
A systematic review and meta-analysis of 27 studies involving 88,830 participants found that intensive blood…
This website uses cookies.